TCT-763: Aortic valve calcium scoring (AVCS) is a predictor of significant paravalvular aortic insufficiency in transapical aortic valve implantation  by unknown
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
In summary, 16.4% of patients (group 1+3) were formally not treatable using TAVI.
Conclusion: The majority of patients with AVS scheduled for TAVI show suitable
AAS for current devices. Anyhow, a substantial number of patients are not eligible due
to oversized aortic annulus diameters. Consecutively, the development of larger
prostheses is crucial to embrace this not negligible minority of patients.
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Background: The occurrence of conduction abnormalities requiring the implantation
of a permanent pacemaker (PPM) in patients undergoing transcatheter aortic valve
implantation (TAVI) is not rare, with an incidence ranging between 5-30% in published
series. To investigate the impact of PPM on prognosis, we compared clinical outcomes
of patients with severe aortic valve stenosis undergoing TAVI in the following three
groups: (1) patients with PPM prior to TAVI, (2) patients with TAVI-related PPM and
(3) patients without PPM before and after TAVI.
Methods: A total of 351 consecutive patients (mean age 82.1±6.7 years, mean
logEuroscore 24.2±15.4%) with symptomatic aortic valve stenosis (mean gradient
44.6±16.3mmHg) undergoing TAVI with use of the 18F Medtronic CoreValve
prosthesis (n=293, 83.5%; transfemoral: 288, subclavian: 5) or the Edwards Sapien
prosthesis (n=58, 16.5%, transfemoral: 24, transapical: 34) were prospectively followed
in this two-center observational study. A total of 47 patients (13.4%) had a PPM prior
to TAVI (group 1), 98 patients (27.9%) received a PPM during the peri-procedural
period (group 2) and 206 patients required no PPM during follow-up (group 3). The
primary endpoint of the study was mortality at one year follow-up. Secondary
endpoints included in-hospital mortality as well as rates of stroke and myocardial
infarction in-hospital and at one year.
Results: Device success was 97.4% without differences between the three groups. In-
hospital and one-year follow-up was available in 100% of alive patients. Overall
in-hospital and one year mortality were 4.6% (16/351) and 22.8% (80/351),
respectively, without significant differences among the different study groups (see
table). Rates of in-hospital stroke, infarction and access site complication were 2.6%,
0.9%, 13.7%. Detailed clinical follow-up will be presented.
Conclusion: In this observational study, patients with severe aortic stenosis undergoing
TAVI had a similar survival independent of the need of PPM implantation, which
underlines the benign nature of this complication.
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Background: Periprocedural myocardial injury (PMI) is a common complication
during cardiac surgery and percutaneous coronary intervention and is an important
predictor for postprocedural cardiovascular morbidity and mortality. Very few data
have been reported about the occurrence of myocardial damage associated with
transcatheter aortic valve implantation (TAVI). Therefore, our purpose was to
investigate the incidence, the predictive factors and clinical consequences of PMI
during TAVI.
Methods: In a prospective observational single-centre study, we included 117 patients
(age 81±8 years, 46 male), who had undergone a TAVI with the Medtronic-CoreValve®
bioprosthesis. Serum CK-MB and cTnT levels were measured pre- and
postprocedurally. Periprocedural myocardial injury was defined as a postprocedural
increase of CK-MB and/or cTnT level above 5 times the upper reference limit, as
obtained from the Valve Academic Research Consortium.
Results: Following TAVI the incidence of PMI was 18%. Independent predictive
factors for PMI were procedural duration (minutes, OR: 1.04; 95%CI: 1.01-1.07),
preprocedural beta-blocker use (OR: 0.13; 95%CI: 0.03-0.51), peripheral arterial
disease (OR: 6.08; 95%CI: 1.47-25.13) and prosthesis depth (millimeters, OR: 1.28;
95%CI: 1.05-1.56). Mortality within 30 days following TAVI was 13%. Predictive
factors identified for 30-day mortality were PMI (OR: 10.89; 95%CI: 2.49-47.53),
preprocedural hospitalization (OR: 9.96; 95%CI: 2.32-42.66) and left ventricular mass
index (gr/m2, OR: 1.02; 95%CI: 1.00-1.03).
Conclusion: Following transcatheter aortic valve implantation, serum levels of both
CK-MB and cTnT increase, which reflects the occurrence of periprocedural myocardial
injury. A longer procedural duration, the absence of beta-blocker use, peripheral arterial
disease and a deeper prosthesis insertion are associated with PMI. Together with
preprocedural hospitalization and left ventricular mass, PMI
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Background: Transapical aortic valve implantation (TA-AVI) has evolved as a routine
for selected high-risk patients. However, paravalvular leaks >1+ remain an unsolved
issue using current generation of transcatheter valve devices. The aim was to study the
impact of aortic valve calcification on paravalvular leaks and outcome using the
Edwards SAPIENTM prosthesis.
Methods: 120 consecutive patients (out of 307 TA-AVIs) with preoperative computed
tomography, age 82.6±6.2 years, 75.0% female, were included. Implanted prosthetic
valve sizes were 23 mm (n=31), and 26 mm (n=89), respectively. Mean logistic
EuroSCORE was 30.1±15.5 and mean STS-Score 12.8±7.9. ECG-gated cardiac CT
allowed to quantify the amount of calcification of aortic valve leaflets using a scoring
analogous to the Agatston calcium scoring of coronary arteries (AVCS). Paravalvular
leaks were assessed intraoperatively by echocardiography and angiography.
Results: All valves were implanted successfully. Mean AVCS in patients without
paravalvular leaks (n=66) was 2704±1510, with mild paravalvular leaks (n=31)
3804±2739 (p=0.05) and with moderate paravalvular leaks (n=4) 7387±1044
(p=0.002). There was a significant correlation between AVCS and paravalvular leaks
(r=0.334; p=0.001) indicating, of note, only a limited degree of linear dependence. No
correlation was found to 30-day mortality, postoperative pacemaker-implantation and
stroke-rate (r=0.040, p=0.671; r=0.117, p=0.232 and r=-0.025, p=0.792). Overall 30-
day mortality was 14.2%.
Conclusion: The AVCS identifies patients at risk for a relevant paravalvular leak.
AVCS prior to TA-AVI might serve as an additional tool to reconsider the TAVI
indication and valve size to reduce the risk of paravalvular leaks.
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Background: The influence of moderate or severe MR on TAVR outcomes is
unknown.
Methods: This study included 535 consecutive patients undergoing TAVR with a
balloon expandable valve at 2 centers. Patients with moderate or severe MR before
TAVR were compared to patients with none or mild MR. .
Results: A total of 149 patients (28%) presented with concomitant moderate or severe
MR and 386 (72%) had none, trivial or mild MR. Patients with moderate or severe
MR were older (median age 84 vs. 82 years, p = 0.01) and exhibited a higher risk
profile (median STS score 8.2 vs. 7.4 %, p = 0.01). MR improved from moderate or
severe to none or mild at discharge in 79/148 (53%) patients and worsened from none
or mild to moderate or severe in 16/379 (4%). Survival rates for patients with and
without moderate or severe MR at baseline were 85.0% and 93.4% at 30 days, 72.3%
and 79.2% at 1 year, and 53.4% and 51.8% at 3 years, respectively (logrank p = 0.038,
Figure). Moderate or severe MR was an independent risk factor for mortality during
the first 30 days (unadjusted HR 2.32 (95% CI 1.31, 4.11), p < 0.01, adjusted HR 2.25
(1.25, 4.05), p < 0.01), but not after 30 days (unadjusted HR 1.03 (0.57, 1.85), p =
0.92, adjusted HR 1.04 (0.57, 1.90), p = 0.90). At 1 year follow-up, only 4% of the
patients with moderate or severe MR at baseline and 5% of the patients with none or
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